GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 339.5 GBX 0.41% Market Closed
Market Cap: 54.7B GBX
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

GlaxoSmithKline PLC
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GlaxoSmithKline PLC
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
GlaxoSmithKline PLC
LSE:GSK
Total Assets
ÂŁ58.1B
CAGR 3-Years
-9%
CAGR 5-Years
-2%
CAGR 10-Years
4%
AstraZeneca PLC
LSE:AZN
Total Assets
$104.3B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
6%
Verona Pharma PLC
NASDAQ:VRNA
Total Assets
$381.8m
CAGR 3-Years
24%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Total Assets
$1.5B
CAGR 3-Years
-3%
CAGR 5-Years
0%
CAGR 10-Years
13%
Hikma Pharmaceuticals PLC
LSE:HIK
Total Assets
$4.8B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
9%
Dechra Pharmaceuticals PLC
LSE:DPH
Total Assets
ÂŁ1.6B
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
14%
No Stocks Found

GlaxoSmithKline PLC
Glance View

Market Cap
54.6B GBX
Industry
Pharmaceuticals

Once upon a time, in the bustling world of pharmaceuticals, GlaxoSmithKline PLC established itself as a formidable player. Born out of mergers and continuous evolution, GSK, as it is commonly known, carved its place in the competitive landscape through strategic research and pioneering innovations. The company operates at the intersection of pharmaceuticals, vaccines, and consumer healthcare, leveraging its breadth to tackle some of the world's most pressing health challenges. From its bustling laboratories to clinical trials, and finally to market, GSK is driven by a mission to improve the quality of human life. Its intricate network of research facilities and production plants stretch across the globe, working tirelessly to develop essential medications and vaccines that span a variety of therapeutic areas including respiratory, HIV, oncology, and immunology. GSK’s revenue streams flow from a well-diversified portfolio. The pharmaceutical division, representing the lion’s share, innovates and produces transformative medicines. Its vaccines division stands strong, leading with essential inoculations that prevent childhood and adult diseases, while the consumer healthcare segment provides everyday wellness products ranging from pain relief to vitamins and skincare. This triad not only underscores GSK’s dynamic adaptability to market needs but also highlights its resilience in weathering the cyclical nature of the healthcare industry. With a keen eye on long-term value and sustained investment in research and development, GSK continues to create a bridge between scientific advancements and societal well-being, defining its role as both a scientific leader and a profit-driven enterprise.

GSK Intrinsic Value
2 340.58 GBX
Undervaluation 43%
Intrinsic Value
Price

See Also

What is GlaxoSmithKline PLC's Total Assets?
Total Assets
58.1B GBP

Based on the financial report for Jun 30, 2024, GlaxoSmithKline PLC's Total Assets amounts to 58.1B GBP.

What is GlaxoSmithKline PLC's Total Assets growth rate?
Total Assets CAGR 10Y
4%

Over the last year, the Total Assets growth was -2%. The average annual Total Assets growth rates for GlaxoSmithKline PLC have been -9% over the past three years , -2% over the past five years , and 4% over the past ten years .

Back to Top